Loading...

NUVL NUVALENT INC US FDA Inspections 8-K Filing

NVLN

NVL

NUVALENT INC

(NUVL)

2024 8-K

Financial Results Update

New Drug Application

Financial Results Update

Financial Estimate Release

Royalty Acquisition

Stock Offering Announcement

Positive Data Report

Financial Results Update

New Drug Filing

Financial Statements

Clinical Trials

Product Expansion

Financial Statements

Board Resignation

Financial Results

Corporate Updates

New Director Elected

Financial Results

Clinical Trial Update

Financial Results Announcement

Clinical Trial Initiation

Annual Meeting Voting Results

FDA Breakthrough Therapy De...

Financial Results Announcement

Financial Results Announcement

Financial Condition

Financial Results Announcement

Underwriting Agreement

Clinical Data Update

Clinical Data Announcement

Financial Results Announcement

Annual Meeting and Amendmen...

Financial Results Announcement

Financial Results Announcement

Monitoring SVB's receivership

External Links:

Nuvalent, Inc. announced the initiation of its Phase 1a/1b clinical trial for its novel HER2-selective inhibitor, NVL-330, for pre-treated patients with HER2-altered non-small cell lung cancer.

AI Assistant

NUVALENT INC

2024

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.